Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Chad E Mire; Robert W Cross; Joan B Geisbert; Viktoriya Borisevich; Krystle N Agans; Daniel J Deer; Megan L Heinrich; Megan M Rowland; Augustine Goba; Mambu Momoh; Mathew L Boisen; Donald S Grant; Mohamed Fullah; Sheik Humarr Khan; Karla A Fenton; James E Robinson; Luis M Branco; Robert F Garry; Thomas W Geisbert

doi:10.1038/nm.4396

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4.

Authors

Chad E Mire^{1

2}, Robert W Cross^{1

2}, Joan B Geisbert^{1

2}, Viktoriya Borisevich^{1

2}, Krystle N Agans^{1

2}, Daniel J Deer^{1

2}, Megan L Heinrich³, Megan M Rowland³, Augustine Goba^{4

5}, Mambu Momoh^{4

5

6}, Mathew L Boisen³, Donald S Grant^{4

5}, Mohamed Fullah^{4

5}, Sheik Humarr Khan^{4

5}, Karla A Fenton^{1

2}, James E Robinson⁷, Luis M Branco³, Robert F Garry^{3

8

9}, Thomas W Geisbert^{1

2}

Affiliations

¹ Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, Texas, USA.
² Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, Texas, USA.
³ Zalgen Labs, Germantown, Maryland, USA.
⁴ Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
⁵ Ministry of Health and Sanitation, Freetown, Sierra Leone.
⁶ Polytechnic College, Kenema, Sierra Leone.
⁷ Sections of Infectious Disease, Departments of Pediatrics and Internal Medicine, School of Medicine, Tulane University, New Orleans, Louisiana, USA.
⁸ Department of Microbiology and Immunology, Tulane University, New Orleans, Louisiana, USA.
⁹ Tulane Center of Excellence, Global Viral Network, Tulane University, New Orleans, Louisiana, USA.

PMID: 28869611
PMCID: PMC5719877
DOI: 10.1038/nm.4396

Abstract

There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.

MeSH terms

Animals
Antibodies, Monoclonal / therapeutic use*
Antibodies, Neutralizing / therapeutic use*
Antibodies, Viral / therapeutic use*
Cross Reactions
Enzyme-Linked Immunosorbent Assay
Humans
Immune Evasion / genetics
Immunohistochemistry
Lassa Fever / prevention & control*
Lassa virus / genetics
Macaca fascicularis
RNA, Viral / blood
Random Allocation
Survival Rate
Viral Load

Substances

Antibodies, Monoclonal
Antibodies, Neutralizing
Antibodies, Viral
RNA, Viral

Abstract

MeSH terms

Substances

Grants and funding